BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80 By: Reuters: Company News May 08, 2018 at 16:11 PM EDT * EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018 Read More >> Related Stocks: Arena Pharmaceuticals